Find Clinical Trials

Answer each question to find trials that best match your clinical situation. You can leave questions blank if you do not know the answer.

This search will output a list of trials for which you may be eligible based on the criteria you enter.

I want to enter information about my cancer and treatments

Results

For more information please click on the clinical trial number and you will be taken to the clinicaltrials.gov website.

Clinical Trial Phase Eligible Participant Official Title Drugs in Trial Location
NCT02855944IIIRecurrent or progressive high grade serous or endometrioid ovarian cancer with BRCA1/2 mutations (>1 prior therapy)ARIEL4 (Assessment of Rucaparib In Ovarian CancEr TriaL): A Phase 3 Multicenter, Randomized Study of Rucaparib Versus Chemotherapy in Patients With Relapsed, BRCA Mutant, High Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal CancerView DrugsColorado, Georgia
Drug(s) in Trial Other Drug Names Main Known Action
RucaparibAG-014699, PF 01367338, CO-338, RubracaPARP inhibitor
NCT01851369IIAdvanced solid tumors and granulosa cell ovarian cancer (in expansion)A Phase I/II Trial of TRC102 (Methoxyamine HCl) in Combination With Temozolomide in Patients With Relapsed Solid Tumors and LymphomasView DrugsMaryland
Drug(s) in Trial Other Drug Names Main Known Action
methoxyamineTRC102Base excision repair inhibitor
TemozolomideTemodal, Temodar, MethazolastoneDNA damaging agent
NCT02576444IIAdvanced solid tumors with AKT, ARID1A, ATM, CDKN2A, CHEK2, IDH1/2, KRAS, MRE11A, PIK3CA, PTEN, TP53 and other HDR gene mutationsA Phase II Study of the PARP Inhibitor Olaparib (AZD2281) Alone and in Combination With AZD1775, AZD5363, or AZD6738 in Advanced Solid TumorsView DrugsConnecticut, Massachusetts, Ohio, Tennessee
Drug(s) in Trial Other Drug Names Main Known Action
AdavosertibWEE1 inhibitor AZD1775, MK1775, AZD1775WEE1 inhibitor
CapivasertibAkt inhibitor AZD5363pan-AKT inhibitor
CeralasertibAZD6738ATR kinase inhibitor
OlaparibAZD2281, LynparzaPARP inhibitor
NCT02571725IIRecurrent ovarian cancer with germline BRCA1/2 mutations (no prior anti-CTLA-4 mAb)A Phase 1-2 Study of the Combination of Olaparib and Tremelimumab, in BRCA1 and BRCA2 Mutation Carriers With Recurrent Ovarian CancerView DrugsFlorida, New Mexico, Ohio, Virginia
Drug(s) in Trial Other Drug Names Main Known Action
OlaparibAZD2281, LynparzaPARP inhibitor
Tremelimumabanti-CTLA4 human monoclonal antibody CP-675,206, CP-675, CP-675,206, CP-675206, TicilimumabBlocks CTLA-4 inhibition of T cells
NCT02843165IIAdvanced solid tumors with lesion treatable with radiotherapyRandomized Phase II Study of Checkpoint Blockade Immunotherapy Combined With Stereotactic Body Radiation Therapy in Advanced Metastatic DiseaseView DrugsCalifornia
Drug(s) in Trial Other Drug Names Main Known Action
AtezolizumabTecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446Blocks PD-L1 inhibition of T cells
IpilimumabAnti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, YervoyBlocks CTLA-4 inhibition of T cells
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cells
PembrolizumabMK3475, SCH 900475, Lambrolizumab, KeytrudaBlocks PD-L1/2 inhibition of T cells
Radiation TherapyRadiotherapy, Irradiation
NCT03348631IIRecurrent or persistent endometrioid/clear cell ovarian cancerA Phase II Study of Tazemetostat (EPZ-6438) in Recurrent Endometrioid/Clear Cell Carcinoma of the Ovary or Peritoneum, and Recurrent Low Grade Endometrioid Endometrial AdenocarcinomaView DrugsAlaska, Arizona, Arkansas, California, Florida, Georgia, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Massachusetts, Michigan, Minnesota, Missouri, Montana, Nebraska, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Dakota, Virginia, Washington, Wisconsin, Wyoming
Drug(s) in Trial Other Drug Names Main Known Action
Tazemetostathistone methyl transferase EZH2 inhibitor E7438, EPZ6438, E7438EZH2 histone methyltransferase inhibitor
NCT02832167IIAdvanced solid tumorsAn Open Label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic MalignanciesView DrugsArizona, California, Colorado, Florida, Illinois, Indiana, Maryland, Minnesota, Missouri, Nebraska, Nevada, New Jersey, New York, Oregon, South Carolina, Tennessee, Texas, Virginia
Drug(s) in Trial Other Drug Names Main Known Action
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cells
NCT03428802IIAdvanced solid tumors with POLE, POLD, or BRCA1/2 mutationsA Basket Trial of Pembrolizumab in Patients With Advanced Solid Tumors and Genomic InstabilityView DrugsNew Jersey
Drug(s) in Trial Other Drug Names Main Known Action
PembrolizumabMK3475, SCH 900475, Lambrolizumab, KeytrudaBlocks PD-L1/2 inhibition of T cells
NCT03462342IIRecurrent ovarian cancerCombination ATR and PARP Inhibitor (CAPRI) Trial With AZD 6738 and Olaparib in Recurrent Ovarian CancerView DrugsPennsylvania
Drug(s) in Trial Other Drug Names Main Known Action
CeralasertibAZD6738ATR kinase inhibitor
OlaparibAZD2281, LynparzaPARP inhibitor
NCT01876511IIAdvanced solid tumors with positive MSI or tumors with negative MSI and high TMBPhase 2 Study of MK-3475 in Patients With Microsatellite Unstable (MSI) TumorsView DrugsCalifornia, Maryland, New York, Ohio, Oregon, Pennsylvania
Drug(s) in Trial Other Drug Names Main Known Action
PembrolizumabMK3475, SCH 900475, Lambrolizumab, KeytrudaBlocks PD-L1/2 inhibition of T cells
NCT03570619IIAdvanced solid tumors with CDK12 alterationsIMPACT: Immunotherapy in Patients With Metastatic Cancers and CDK12 MutationsView DrugsFlorida, Michigan, New York
Drug(s) in Trial Other Drug Names Main Known Action
IpilimumabAnti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, YervoyBlocks CTLA-4 inhibition of T cells
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cells
NCT03579316IIRecurrent ovarian cancer (PD on or after prior PARP inhibitor)A Randomized 2-Arm, Non-Comparative Phase 2 Study of AZD1775 Alone or AZD1775 and Olaparib in Ovarian Cancer Patients Who Have Progressed During PARP InhibitionView DrugsMassachusetts, Texas
Drug(s) in Trial Other Drug Names Main Known Action
AdavosertibWEE1 inhibitor AZD1775, MK1775, AZD1775WEE1 inhibitor
OlaparibAZD2281, LynparzaPARP inhibitor
NCT03610490IIRecurrent or refractory high grade serous ovarian cancer or carcinosarcomaClinical Study to Assess Efficacy and Safety of MDA-TIL (Autologous Expanded Tumor Infiltrating Lymphocytes) Across Multiple Tumor TypesView DrugsTexas
Drug(s) in Trial Other Drug Names Main Known Action
MDA-TILautologous tumor-infiltrating lymphocytes MDA-TILAnti-tumor immune response
NCT03651271IIRecurrent ovarian cancer with high MSIAn Exploratory Study of Nivolumab With or Without Ipilimumab According to the Percentage of Tumoral CD8 Cells in Participants With Advanced Metastatic CancerView DrugsCalifornia, Massachusetts, New York, Texas
Drug(s) in Trial Other Drug Names Main Known Action
IpilimumabAnti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, YervoyBlocks CTLA-4 inhibition of T cells
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cells
NCT03693014IIAdvanced solid tumors with limited progression on checkpoint inhibitor treatmentA Phase II Trial of Hypofractionated Radiotherapy in Patients With Limited Progression on Immune Checkpoint BlockadeView DrugsNew Jersey, New York
Drug(s) in Trial Other Drug Names Main Known Action
AtezolizumabTecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446Blocks PD-L1 inhibition of T cells
IpilimumabAnti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, YervoyBlocks CTLA-4 inhibition of T cells
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cells
PembrolizumabMK3475, SCH 900475, Lambrolizumab, KeytrudaBlocks PD-L1/2 inhibition of T cells
Radiation TherapyRadiotherapy, Irradiation
NCT03732950IIRecurrent ovarian cancerA Phase II Study of Pembrolizumab Monotherapy in Recurrent Ovarian Cancer of the Immunoreactive Subtype Determined by NanoString Gene Expression ProfilingView DrugsCalifornia, Minnesota
Drug(s) in Trial Other Drug Names Main Known Action
PembrolizumabMK3475, SCH 900475, Lambrolizumab, KeytrudaBlocks PD-L1/2 inhibition of T cells
NCT03734692IIPlatinum sensitive ovarian cancer with first or second recurrence in peritoneal cavitySystemic Immune Checkpoint Blockade and Intraperitoneal Chemo-Immunotherapy in Recurrent Ovarian CancerView DrugsPennsylvania
Drug(s) in Trial Other Drug Names Main Known Action
CisplatinCACP, cis-DDP, cis-platinum, CDDP, Platinol, Abiplatin, Blastolem, Briplatin, Cisplatyl, Citoplatino, Citosin, Lederplatin, Metaplatin, Neoplatin, Placis, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platiran, Platistin, PlatosinDNA damaging agent
PembrolizumabMK3475, SCH 900475, Lambrolizumab, KeytrudaBlocks PD-L1/2 inhibition of T cells
RintatolimodAtvogen, AmpligenTLR-3 agonist and immune cell stimulator
NCT03673124IILow grade serous ovarian cancerA Phase II Trial of Ribociclib (LEE011) Plus Letrozole in Women With Recurrent Low-Grade Serous Carcinoma of the Ovary or PeritoneumView DrugsOklahoma
Drug(s) in Trial Other Drug Names Main Known Action
LetrozoleFemaraAromatase inhibitor
RibociclibKisqali, CDK4/6 Inhibitor LEE011, LEE011, KisqaliCDK4/6 inhibitor
NCT03742895IIAdvanced BRCA1/2-wild type solid tumors with DNA repair gene mutations (e.g., ATM, PALB2, RAD51D) or HRD+A Phase 2 Study of Olaparib Monotherapy in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced CancerView DrugsCalifornia, Georgia, Kentucky, Massachusetts, Michigan, Nebraska, New York, Oklahoma, Pennsylvania, South Dakota, Washington
Drug(s) in Trial Other Drug Names Main Known Action
OlaparibAZD2281, LynparzaPARP inhibitor
NCT03836352IIRecurrent ovarian cancer (with tumor lesions < 5 cm)A Phase 2, Open-label, Multicenter, Study of an Immunotherapeutic Treatment, DPX-Survivac in Combination With Low Dose Cyclophosphamide and Pembrolizumab, in Subjects With Selected Advanced and Recurrent Solid Tumours.View DrugsNew York, Texas
Drug(s) in Trial Other Drug Names Main Known Action
CyclophosphamideCiclofosfamida, Ciclofosfamide, Claphene, CP monohydrate, CPM, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphanum, Cytophosphane, Mitoxan, Syklofosfamid, Zytoxan, Clafen, Cytoxan, Neosar, Carloxan, Cicloxal, Cycloblastin, Cycloblastine, CYCLO-cell, Cyclostin, Cyclostine, Cytophosphan, Endoxan, Endoxana, Enduxan, Fosfaseron, Genoxal, Ledoxina, Procytox, SendoxanDNA damaging agent
DPX-Survivacsurvivin antigen vaccine DPX-SurvivacImmune response against cancer expressing survivin
PembrolizumabMK3475, SCH 900475, Lambrolizumab, KeytrudaBlocks PD-L1/2 inhibition of T cells
NCT03461952IIAdvanced solid tumors with POLE and/or POLD1 mutationsA Phase II Open Label, Randomized Non-Comparative Trial of Nivolumab Alone or in Combination With Ipilimumab for the Treatment of Patients With Advanced Hypermutated Solid Tumors Detected by a Blood Based AssayView DrugsNew York
Drug(s) in Trial Other Drug Names Main Known Action
IpilimumabAnti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, YervoyBlocks CTLA-4 inhibition of T cells
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cells
NCT03697304IIAdvanced solid tumors with prior PD-1/PD-L1 targeted treatmentAn Open-label, Phase II, Platform Trial Evaluating Safety and Efficacy of Multiple BI 754091 Anti-PD-1 Based Combination Regimens in PD-(L)1 naïve and PD-(L)1 Pretreated Patient Populations With Advanced and/or Metastatic Solid Tumours Who Have Had at Least One Line of Systemic TherapyView DrugsCalifornia
Drug(s) in Trial Other Drug Names Main Known Action
BI 754091anti-PD-1 monoclonal antibody BI 754091Blocks PD-L1/2 inhibition of T cells
BI 754111Blocks LAG-3 inhibition of T cells
NCT03878849IIRecurrent ovarian cancerPhase II, Prospective Open Label, Single Arm Study to Investigate Anti-tumor Effect and Tolerability of 2X-121 in Patients With Advanced Ovarian Cancer Selected by the 2X-121 DRP®View DrugsMassachusetts
Drug(s) in Trial Other Drug Names Main Known Action
2X-121PARP inhibitor
NCT02819843IIAdvanced solid tumors - intratumoral injectionA Phase II Randomized Trial of Intralesional Talimogene Laherparepvec (TALIMOGENE LAHERPAREPVEC) With or Without Radiotherapy for Cutaneous Melanoma, Merkel Cell Carcinoma, or Other Solid TumorsView DrugsNew Jersey, New York
Drug(s) in Trial Other Drug Names Main Known Action
Radiation TherapyRadiotherapy, Irradiation
Talimogene LaherparepvecGM-CSF-encoding oncolytic herpes simplex virus, T-VECInduces immune response and tumor cell lysis
NCT03909152IIRecurrent PR+ low grade serous or granulosa cell ovarian cancerBasket Study of the Oral Progesterone Antagonist Onapristone ER (Apristor) in Women With Progesterone Receptor Positive (PR+) Recurrent Granulosa Cell Tumor, Low Grade Serous Ovarian Cancer or Endometrioid Endometrial CancerView DrugsNew Jersey, New York
Drug(s) in Trial Other Drug Names Main Known Action
Onapristone ERextended-release onapristonePR antagonist that blocks PR activation and the associated expression of PR-responsive genes
NCT03911557IIAdvanced solid tumors with moderate/high TMBPhase 2 Investigation of MEDI4736 (Durvalumab) and Tremelimumab Combination in Somatically Hypermutated Recurrent Solid TumorsView DrugsKentucky
Drug(s) in Trial Other Drug Names Main Known Action
DurvalumabAnti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, ImfinziBlocks PD-L1 inhibition of T cells
Tremelimumabanti-CTLA4 human monoclonal antibody CP-675,206, CP-675, CP-675,206, CP-675206, TicilimumabBlocks CTLA-4 inhibition of T cells
NCT02710253IIAdvanced solid tumors with progression on systemic immunotherapyPhase II Trial of Salvage Radiation Therapy to Induce Systemic Disease Regression After Progression on Systemic ImmunotherapyView DrugsTexas
Drug(s) in Trial Other Drug Names Main Known Action
Radiation TherapyRadiotherapy, Irradiation
NCT03616834IIAdvanced solid tumors with high MSI on checkpoint inhibitor treatment without evidence of complete or partial responseTomivosertib (eFT-508) in Combination With PD-1/PD-L1 Inhibitor Therapy: A Study of Subjects Administered Anti-PD-1/Anti-PD-L1 Therapy That Are Experiencing Insufficient Response to Checkpoint Inhibitor AloneView DrugsArizona, California, Georgia, Idaho, Indiana, Maryland, Michigan, Ohio, Oregon, South Carolina, South Dakota, Texas, Virginia, Wisconsin
Drug(s) in Trial Other Drug Names Main Known Action
TomivosertibeFT508MNK1/2 inhibitor
NCT03449108IIRecurrent or refractory high grade serous ovarian cancer or carcinosarcomaClinical Study to Assess Efficacy and Safety of LN-145 (Autologous Centrally Manufactured Tumor Infiltrating Lymphocytes) Across Multiple Tumor TypesView DrugsTexas
Drug(s) in Trial Other Drug Names Main Known Action
AldesleukinIL-2 receptor agonist
CyclophosphamideCiclofosfamida, Ciclofosfamide, Claphene, CP monohydrate, CPM, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphanum, Cytophosphane, Mitoxan, Syklofosfamid, Zytoxan, Clafen, Cytoxan, Neosar, Carloxan, Cicloxal, Cycloblastin, Cycloblastine, CYCLO-cell, Cyclostin, Cyclostine, Cytophosphan, Endoxan, Endoxana, Enduxan, Fosfaseron, Genoxal, Ledoxina, Procytox, SendoxanDNA damaging agent
FludarabineFludara Oral, 2-F-ara-AMP, BeneflurDNA synthesis inhibitor
LN-145autologous tumor infiltrating lymphocytes LN-145, autologous TILs LN-145Anti-tumor immune response
NCT03704467Ib/IIPlatinum sensitive ovarian cancer with disease progression following maintenance treatment with a PARP inhibitor (at least 2 prior platinum therapies)A Phase Ib Safety Run-in and Randomized Phase II, Open-label Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of M6620 in Combination With Avelumab and Carboplatin in Comparison to Standard of Care Therapy in Participants With PARPi-resistant Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube CancerView DrugsAlabama, Alaska, Arkansas, California, Connecticut, Georgia, Maine, Massachusetts, Michigan, New Jersey, New York, Oklahoma, Rhode Island, Texas
Drug(s) in Trial Other Drug Names Main Known Action
AvelumabAnti programmed death ligand 1 monoclonal antibody, Anti-PD-L1, MSB0010718C, BavencioBlocks PD-L1 inhibition of T cells
BerzosertibVX-970, M6620, VE-822, ATR kinase inhibitor VX-970ATR kinase inhibitor
Bevacizumabimmunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, AvastinVEGF antagonist
CarboplatinParaplatin, NovoplatinumDNA damaging agent
GemcitabineGemzarRibonucleotide reductase and DNA synthesis inhibitor
Liposomal doxorubicinDoxil, Dox-SL, Evacet, LipoDox, liposomal doxorubicin, Pegylated Liposomal Doxorubicin HydrochlorideTopoisomerase II inhibitor
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXLMicrotubule stabilizer/mitotic inhibitor
NCT03717415Ib/IIAdvanced solid tumorsAn Open Label, Multicenter, Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination With Carboplatin to Assess Safety, Tolerability, and Pharmacokinetics in Patients With Advanced or Metastatic Solid TumorsView DrugsCalifornia, Texas
Drug(s) in Trial Other Drug Names Main Known Action
CarboplatinParaplatin, NovoplatinumDNA damaging agent
Rebastinibmultitargeted tyrosine kinase inhibitor DCC-2036Multi-targeted kinase inhibitor
NCT03330405Ib/IIPlatinum sensitive recurrent ovarian cancerA Phase 1b/2 Study To Evaluate Safety And Anti Tumor Activity Of Avelumab In Combination With The Poly(Adenosine Diphosphate [Adp]-Ribose) Polymerase (Parp) Inhibitor Talazoparib In Patients With Locally Advanced Or Metastatic Solid TumorsView DrugsArkansas, California, District of Columbia, Massachusetts, Michigan, Minnesota, New York, Ohio, Pennsylvania, Texas
Drug(s) in Trial Other Drug Names Main Known Action
AvelumabAnti programmed death ligand 1 monoclonal antibody, Anti-PD-L1, MSB0010718C, BavencioBlocks PD-L1 inhibition of T cells
TalazoparibTalazoparib Tosylate, BMN-673, MDV3800PARP inhibitor
NCT02606305Ib/IIAdvanced FRalpha+ ovarian cancerA Phase 1b/2 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Mirvetuximab Soravtansine (IMGN853) in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab+Carboplatin in Adults With Folate Receptor Alpha Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube CancerView DrugsAlabama, California, Massachusetts, Nevada, Ohio, Oklahoma, Pennsylvania
Drug(s) in Trial Other Drug Names Main Known Action
Bevacizumabimmunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, AvastinVEGF antagonist
Mirvetuximab SoravtansineM9346A-sulfo-SPDB-DM4, IMGN853, Anti-FOLR1-mab Maytansinoid ConjugateADC: anti-FOLR1 + microtubule destabilizer (DM4)
NCT02785250Ib/IIRecurrent ovarian cancerA Phase 1b/2 Study of an Immunotherapeutic Vaccine, DPX-Survivac With Low Dose Cyclophosphamide and Epacadostat (INCB024360) in Patients With Recurrent Ovarian CancerView DrugsCalifornia, Georgia, New York, Oregon, Pennsylvania, Texas
Drug(s) in Trial Other Drug Names Main Known Action
CyclophosphamideCiclofosfamida, Ciclofosfamide, Claphene, CP monohydrate, CPM, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphanum, Cytophosphane, Mitoxan, Syklofosfamid, Zytoxan, Clafen, Cytoxan, Neosar, Carloxan, Cicloxal, Cycloblastin, Cycloblastine, CYCLO-cell, Cyclostin, Cyclostine, Cytophosphan, Endoxan, Endoxana, Enduxan, Fosfaseron, Genoxal, Ledoxina, Procytox, SendoxanDNA damaging agent
DPX-Survivacsurvivin antigen vaccine DPX-SurvivacImmune response against cancer expressing survivin
NCT02994953IbAdvanced solid tumorsA Phase Ib Open‑Label, Dose‑Finding Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of Avelumab in Combination With M9241(NHS-IL12) in Subjects With Locally Advanced, Unresectable, or Metastatic Solid TumorsView DrugsCalifornia, Connecticut, Florida, Louisiana, Minnesota, Missouri, Ohio, Oklahoma, Oregon, South Carolina, Texas, Vermont, Washington
Drug(s) in Trial Other Drug Names Main Known Action
AvelumabAnti programmed death ligand 1 monoclonal antibody, Anti-PD-L1, MSB0010718C, BavencioBlocks PD-L1 inhibition of T cells
NHS-IL12M9241, immunocytokine NHS-IL12IL-12 receptor agonist
NCT03206177IbNewly diagnosed, persistent, or recurrent ovarian carcinosarcomaFeasibility IB Trial of Paclitaxel/Carboplatin + Galunisertib (a Small Molecule Inhibitor of the Kinase Domain of Type 1 TGF-B Receptor) in Patients With Newly Diagnosed, Persistent or Recurrent Carcinosarcoma of the Uterus or OvaryView DrugsOklahoma
Drug(s) in Trial Other Drug Names Main Known Action
CarboplatinParaplatin, NovoplatinumDNA damaging agent
GalunisertibLY2157299TGFBR1 antagonist
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXLMicrotubule stabilizer/mitotic inhibitor
NCT03307785IbAdvanced solid tumorsPhase 1b Dose-Finding Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042 in Patients With Advanced or Metastatic CancerView DrugsArizona, California, Florida, Michigan, New Mexico, Ohio, Oklahoma, South Carolina, Tennessee, Texas
Drug(s) in Trial Other Drug Names Main Known Action
Bevacizumabimmunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, AvastinVEGF antagonist
CarboplatinParaplatin, NovoplatinumDNA damaging agent
NiraparibMK4827, ZejulaPARP inhibitor
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXLMicrotubule stabilizer/mitotic inhibitor
TSR-022Blocks TIM-3 inhibition of T cells
TSR-042anti-PD-1 monoclonal antibody TSR-042, ANB011, DostarlimabBlocks PD-L1/2 inhibition of T cells
NCT03318445IbAdvanced solid tumors with BRCA1, BRCA2, ATM, BARD1, BRIP1, CDK12, CHEK2, FANCA, NBN, PALB2, RAD51, RAD51B, RAD51C, RAD51D, or RAD54L mutations (inc expansion)Combination Therapy of Rucaparib and Irinotecan in Cancers With Mutations in DNA RepairView DrugsCalifornia
Drug(s) in Trial Other Drug Names Main Known Action
IrinotecanCampothecin-11, Campto, CamptosarTopoisomerase I inhibitor
RucaparibAG-014699, PF 01367338, CO-338, RubracaPARP inhibitor
NCT03695380IbPlatinum sensitive ovarian cancer with ≤ 2 prior platinum therapies (inc expansion)A Phase Ib Study of Cobimetinib Administered in Combination With Niraparib, With or Without Atezolizumab, To Patients With Advanced Platinum-sensitive Ovarian CancerView DrugsArizona, California, Florida, Georgia, Maryland, Missouri, New York, Oklahoma, Tennessee, Wisconsin
Drug(s) in Trial Other Drug Names Main Known Action
AtezolizumabTecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446Blocks PD-L1 inhibition of T cells
CobimetinibCotellic, GDC-0973, XL518MEK1 inhibitor
NiraparibMK4827, ZejulaPARP inhibitor
NCT03586661IbRecurrent ovarian cancer with BRCA1/2 mutations (or high grade serous with BRCA1/2-wild type)(inc expansion)A Phase Ib Study of the Oral PARP Inhibitor Niraparib With the Intravenous PI3K Inhibitor Copanlisib for Recurrent Endometrial and Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube CancerView DrugsTexas
Drug(s) in Trial Other Drug Names Main Known Action
CopanlisibBAY 80-6946, MEK inhibitor BAY 80-6946, PI3K inhibitor BAY 80-6946pan-PI3K inhibitor
NiraparibMK4827, ZejulaPARP inhibitor
NCT03589651IbAdvanced solid tumors (inc expansion)A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid TumorsView DrugsCalifornia, Connecticut, Florida, Illinois, New Jersey, New York, North Carolina, Pennsylvania, Texas, Washington
Drug(s) in Trial Other Drug Names Main Known Action
Epacadostat3-dioxygenase Inhibitor INCB024360, Indoleamine-2,3-dioxygenase Inhibitor INCB024360, INCB024360, IDO1 Inhibitor INCB024360Inhibits IDO1 to stimulate immune response
INCB050465PI3K-delta inhibitor INCB050465PI3K delta inhibitor
MGA012anti-PD-1 monoclonal antibody MGA012, INCMGA00012Blocks PD-L1 inhibition of T cells
NCT03872947IbPlatinum sensitive or partially sensitive ovarian cancerA Phase 1b, Multicenter Study to Determine the Dose, Safety, Efficacy and Pharmacokinetics of TRK-950 When Used in Combinations With Selected Anti-Cancer Treatment Regimens in Patients With Selected Advanced Solid TumorsView DrugsNew Jersey, Wisconsin
Drug(s) in Trial Other Drug Names Main Known Action
CarboplatinParaplatin, NovoplatinumDNA damaging agent
GemcitabineGemzarRibonucleotide reductase and DNA synthesis inhibitor
PembrolizumabMK3475, SCH 900475, Lambrolizumab, KeytrudaBlocks PD-L1/2 inhibition of T cells
TRK-950monoclonal antibody TRK-950Undisclosed mechanism
NCT03514121Ia/IbAdvanced solid tumors (in ovarian expansion)A Phase 1a/1b Study of FPA150, an Anti-B7-H4 Antibody, in Patients With Advanced Solid TumorsView DrugsArizona, California, Connecticut, Illinois, Michigan, Oklahoma, Tennessee, Texas, Utah, Washington
Drug(s) in Trial Other Drug Names Main Known Action
FPA150anti-B7-H4 monoclonal antibody FPA150blocks B7-H4 inhibition of T cells
PembrolizumabMK3475, SCH 900475, Lambrolizumab, KeytrudaBlocks PD-L1/2 inhibition of T cells
NCT03209401Ia/IbAdvanced solid tumors with mutations in ARID1A, ATM, ATRX, MRE11A, NBN, PTEN, RAD50/51/51B, BARD1, BLM, BRCA1/2, BRIP1, FANCA/C/D2/E/F/G/L, PALB2, WRN, CHEK2, CHEK1, BAP1, FAM175A, SLX4, MLL2 or XRCC (inc expansion)Niraparib Plus Carboplatin in Patients With Homologous Recombination Deficient Advanced Solid Tumor MalignanciesView DrugsDistrict of Columbia
Drug(s) in Trial Other Drug Names Main Known Action
CarboplatinParaplatin, NovoplatinumDNA damaging agent
NiraparibMK4827, ZejulaPARP inhibitor
NCT02913313I/IIaAdvanced solid tumorsPhase 1/2a First-In-Human Study of BMS-986207 Monoclonal Antibody Alone and in Combination With Nivolumab in Advanced Solid TumorsView DrugsNew Jersey, New York, Pennsylvania, Utah
Drug(s) in Trial Other Drug Names Main Known Action
BMS-986207anti-TIGIT monoclonal antibody BMS-986207Blocks T cell binding to CD112 and CD155 to enable activation of CD226 signaling in NK and CD8 T cells
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cells
NCT02953457I/IIRecurrent, persistent or refractory high grade serous ovarian cancer with BRCA1/2 or HRD or MMR gene alterations or high LOH/HRD scoresA Phase I/II Evaluation of Olaparib in Combination With Durvalumab (Medi4736) and Tremelimumab in the Treatment of Recurrent Platinum Sensitive or Resistant or Refractory Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Patients Who Carry a BRCA1 or BRCA2 MutationView DrugsNew York
Drug(s) in Trial Other Drug Names Main Known Action
DurvalumabAnti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, ImfinziBlocks PD-L1 inhibition of T cells
OlaparibAZD2281, LynparzaPARP inhibitor
Tremelimumabanti-CTLA4 human monoclonal antibody CP-675,206, CP-675, CP-675,206, CP-675206, TicilimumabBlocks CTLA-4 inhibition of T cells
NCT02484404I/IIRecurrent ovarian cancerPhase I/II Study of the Anti-Programmed Death Ligand-1 Antibody MEDI4736 in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal CancersView DrugsMaryland
Drug(s) in Trial Other Drug Names Main Known Action
CediranibRecentin, Cediranib maleate, AZD2171VEGFR1-3 kinase inhibitor
DurvalumabAnti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, ImfinziBlocks PD-L1 inhibition of T cells
OlaparibAZD2281, LynparzaPARP inhibitor
NCT02487095I/IIExtrapulmonary small cell ovarian cancerA Phase I/II Trial of Topotecan With VX970, an ATR Kinase Inhibitor in Small Cell CancersView DrugsMaryland
Drug(s) in Trial Other Drug Names Main Known Action
BerzosertibVX-970, M6620, VE-822, ATR kinase inhibitor VX-970ATR kinase inhibitor
TopotecanHycamptamine, Hycamtin, TOPOTopoisomerase I inhibitor
NCT02734004I/IIPlatinum sensitive recurrent ovarian cancerA Phase I/II Study of MEDI4736 (Anti-PD-L1 Antibody) in Combination With Olaparib (PARP Inhibitor) in Patients With Advanced Solid TumorsView DrugsGeorgia, Maryland, Massachusetts, Michigan, Missouri, Ohio, Pennsylvania, Texas, Wisconsin
Drug(s) in Trial Other Drug Names Main Known Action
Bevacizumabimmunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, AvastinVEGF antagonist
DurvalumabAnti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, ImfinziBlocks PD-L1 inhibition of T cells
OlaparibAZD2281, LynparzaPARP inhibitor
NCT02432378I/IIPlatinum sensitive ovarian cancer with first recurrence in peritoneal cavity - intranodal injection (inc expansion)A Phase 1-2 Neoadjuvant Dose Finding, Safety, and Immunologic Efficacy Trial of Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer and Tumor-Specific Intranodal Autologous Alpha-DC1 VaccinesView DrugsPennsylvania
Drug(s) in Trial Other Drug Names Main Known Action
Alpha-DC1 vaccineAnti-tumor immune response
CelecoxibCelebrex
CisplatinCACP, cis-DDP, cis-platinum, CDDP, Platinol, Abiplatin, Blastolem, Briplatin, Cisplatyl, Citoplatino, Citosin, Lederplatin, Metaplatin, Neoplatin, Placis, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platiran, Platistin, PlatosinDNA damaging agent
NCT03251924I/IIAdvanced solid tumorsA Phase 1/2 Dose Escalation and Combination Cohort Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Efficacy of BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid TumorsView DrugsMassachusetts, New Jersey, Pennsylvania, Tennessee
Drug(s) in Trial Other Drug Names Main Known Action
BMS-986226anti-ICOS BMS-986226, anti-inducible T-cell co-stimulator BMS-986226Stimulates ICOS to increase T cell activity and immune response
IpilimumabAnti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, YervoyBlocks CTLA-4 inhibition of T cells
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cells
NCT03446040I/IIAdvanced solid tumorsA Phase 1/2 First-in-Human Study of BMS-986258 Alone and in Combination With Nivolumab in Advanced Malignant TumorsView DrugsCalifornia, Colorado, Pennsylvania, Tennessee
Drug(s) in Trial Other Drug Names Main Known Action
BMS-986258anti-TIM3 antibody BMS-986258Blocks TIM-3 inhibition of T cells
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cells
NCT03729596I/IIAdvanced solid tumorsA Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of MGC018 (Anti-B7-H3 Antibody Drug Conjugate) Alone and in Combination With MGA012 (Anti-PD-1 Antibody) in Patients With Advanced Solid TumorsView DrugsMichigan, North Carolina, Virginia
Drug(s) in Trial Other Drug Names Main Known Action
MGA012anti-PD-1 monoclonal antibody MGA012, INCMGA00012Blocks PD-L1 inhibition of T cells
MGC018A humanized anti-B7-H3 antibody conjugated to the vc- seco - DUocarmycin-hydroxyBenzamide-Azaindole (DUBA) 2 DNA alkylating payloadADC: anti-B7-H3 + DNA alkylating agent (Duocarmycin)
NCT03157128I/IIAdvanced solid tumorsA Phase 1/2 Study of Oral LOXO-292 in Patients With Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors With RET Activation (LIBRETTO-001)View DrugsArizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Louisiana, Maryland, Massachusetts, Michigan, Minnesota, Missouri, Nevada, New York, North Carolina, Ohio, Oregon, Pennsylvania, Tennessee, Texas, Utah, Virginia, Wisconsin
Drug(s) in Trial Other Drug Names Main Known Action
LOXO-292RET kinase inhibitor LOXO-292RET-kinase inhibitor
NCT03665285I/IIAdvanced solid tumorsA Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid TumorsView DrugsCalifornia, Connecticut, New Jersey, New York, Texas
Drug(s) in Trial Other Drug Names Main Known Action
NC318anti-S15 monoclonal antibody NC318, anti-Siglec-15 monoclonal antibody NC318Blocks tumor-associated macrophage stimulation of tumor growth
NCT03369223I/IIAdvanced solid tumorsA Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination With Nivolumab in Advanced Solid TumorsView DrugsColorado, Florida, Maryland, New Jersey, New York, Ohio, Oregon, Pennsylvania, South Carolina, Texas, Virginia, Washington
Drug(s) in Trial Other Drug Names Main Known Action
BMS-986249Probody of ipilumumabBlocks CTLA-4 inhibition of T cells
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cells
NCT03761914I/IIRecurrent or persistent WT1+ ovarian cancerA Phase 1/2 Study of Galinpepimut-S in Combination With Pembrolizumab (MK 3475) in Patients With Selected Advanced CancersView DrugsCalifornia, Florida
Drug(s) in Trial Other Drug Names Main Known Action
Galinpepimut-SImmune response against cancer expressing WT1
PembrolizumabMK3475, SCH 900475, Lambrolizumab, KeytrudaBlocks PD-L1/2 inhibition of T cells
NCT03775850I/IIAdvanced MSI-high solid tumors that relapsed following PD-1/L-1 checkpoint inhibitor therapyA Phase I/II Open-label Study of EDP1503 Alone and in Combination With Pembrolizumab in Patients With Advanced Metastatic Colorectal Carcinoma, Triple-negative Breast Cancer, and Checkpoint Inhibitor Relapsed TumorsView DrugsFlorida, Oklahoma, Tennessee
Drug(s) in Trial Other Drug Names Main Known Action
EDP1503monoclonal microbial EDP1503
PembrolizumabMK3475, SCH 900475, Lambrolizumab, KeytrudaBlocks PD-L1/2 inhibition of T cells
NCT03744468I/IIAdvanced solid tumorsPhase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Anti-TIM-3 Monoclonal Antibody BGB-A425 in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid TumorsView DrugsColorado, Pennsylvania
Drug(s) in Trial Other Drug Names Main Known Action
BGB-A425Blocks TIM-3 inhibition of T cells
Tislelizumabanti-PD-1 monoclonal antibody BGB-A317Blocks PD-L1/2 inhibition of T cells
NCT02660034I/IbPlatinum sensitive recurrent ovarian cancer (at least 2 prior platinum therapies)A Phase 1/1b, Open Label, Multiple Dose, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics and Antitumor Activity of the Anti-PD-1 Monoclonal Antibody BGB-A317 in Combination With the PARP Inhibitor BGB-290 in Subjects With Advanced Solid TumorsView DrugsArizona, California, Colorado, Florida, Massachusetts, New York, Pennsylvania, Tennessee, Texas, Virginia
Drug(s) in Trial Other Drug Names Main Known Action
PamiparibPARP inhibitor BGB-290PARP inhibitor
Tislelizumabanti-PD-1 monoclonal antibody BGB-A317Blocks PD-L1/2 inhibition of T cells
NCT03061188I/IbAdvanced solid tumors (inc expansion--ATR, ATM, CHEK1/2, BRCA1/2, BAP1, BARD1, FANCA/C/D2/E, RAD50/51, PALB2, CDK12, POLE, POLD1, PRKDC, ERCC2, POLQ, MRE11A, NBN mutations or FANCA/C/D2/E or EMSY amplification)Phase I/Ib Study of Nivolumab and Veliparib in Patients With Advanced Solid Tumors and Lymphoma With and Without Alterations in Selected DNA Repair GenesView DrugsIllinois
Drug(s) in Trial Other Drug Names Main Known Action
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cells
VeliparibABT-888PARP inhibitor
NCT03054298IRecurrent or persistent mesothelin+ serous ovarian cancerPhase I Study of Human Chimeric Antigen Receptor Modified T Cells in Patients With Mesothelin Expressing CancersView DrugsPennsylvania
Drug(s) in Trial Other Drug Names Main Known Action
CyclophosphamideCiclofosfamida, Ciclofosfamide, Claphene, CP monohydrate, CPM, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphanum, Cytophosphane, Mitoxan, Syklofosfamid, Zytoxan, Clafen, Cytoxan, Neosar, Carloxan, Cicloxal, Cycloblastin, Cycloblastine, CYCLO-cell, Cyclostin, Cyclostine, Cytophosphan, Endoxan, Endoxana, Enduxan, Fosfaseron, Genoxal, Ledoxina, Procytox, SendoxanDNA damaging agent
Hu-CART-meso cellsImmune response against cancer expressing mesothelin
NCT03154281IAdvanced ovarian cancer (no prior PARPi)A Phase 1 Evaluation of the Safety and Tolerability of Niraparib in Combination With Everolimus in Advanced Ovarian and Breast CancerView DrugsSouth Dakota
Drug(s) in Trial Other Drug Names Main Known Action
EverolimusZortress, RAD001, Certican, AfinitormTOR inhibitor
NiraparibMK4827, ZejulaPARP inhibitor
NCT02628574IAdvanced solid tumors (in expansion)A Phase 1 Study of TRX518 Monotherapy and TRX518 in Combination With Gemcitabine, Pembrolizumab, or Nivolumab in Adults With Advanced Solid TumorsView DrugsIllinois, New Mexico, Ohio, Pennsylvania, Tennessee
Drug(s) in Trial Other Drug Names Main Known Action
GemcitabineGemzarRibonucleotide reductase and DNA synthesis inhibitor
PembrolizumabMK3475, SCH 900475, Lambrolizumab, KeytrudaBlocks PD-L1/2 inhibition of T cells
TRX518anti-huGITR monoclonal antibody TRX518, anti-huGITR mAb TRX518, anti-huGITR MoAb TRX518GITR (glucocorticoid-induced TNFR) agonist
NCT01239134IAdvanced solid tumors (in expansion)Part A: A First-in-Human Single Ascending Dose Study of TRX518 in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma or Other Solid Tumor Malignancies Part B: A Dose-Escalation Study of Multi-dose TRX518 Monotherapy Part C: An Expansion Cohort of Multi-dose TRX518 Monotherapy at the Maximum Tolerated DoseView DrugsNew York
Drug(s) in Trial Other Drug Names Main Known Action
TRX518anti-huGITR monoclonal antibody TRX518, anti-huGITR mAb TRX518, anti-huGITR MoAb TRX518GITR (glucocorticoid-induced TNFR) agonist
NCT01376505IAdvanced solid tumors (in ovarian expansion)Phase I Active Immunotherapy Trial With a Combination of Two Chimeric (Trastuzumab-like and Pertuzumab-like)Human Epidermal Growth Factor Receptor 2 (HER-2) B Cell Peptide Vaccine Emulsified in ISA 720 and Nor-MDP Adjuvant in Patients With Advanced Solid TumorsView DrugsOhio
Drug(s) in Trial Other Drug Names Main Known Action
MVF-HER-2(597-626)-MVF-HER-2 (266-296) peptide vaccineImmune response against cancer expressing HER2
NCT03056833IPlatinum sensitive recurrent ovarian cancerPhase I Trial of Ribociclib (Ribociclib (LEE-011)) With Platinum-based Chemotherapy in Recurrent Platinum Sensitive Ovarian CancerView DrugsPennsylvania
Drug(s) in Trial Other Drug Names Main Known Action
CarboplatinParaplatin, NovoplatinumDNA damaging agent
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXLMicrotubule stabilizer/mitotic inhibitor
RibociclibKisqali, CDK4/6 Inhibitor LEE011, LEE011, KisqaliCDK4/6 inhibitor
NCT03289962IAdvanced solid tumorsA Phase 1a/1b Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of RO7198457 as a Single Agent and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic TumorsView DrugsArizona, California, Colorado, Connecticut, District of Columbia, Massachusetts, Nevada, New York, Oklahoma, Oregon, Pennsylvania, Tennessee, Washington
Drug(s) in Trial Other Drug Names Main Known Action
AtezolizumabTecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446Blocks PD-L1 inhibition of T cells
RO7198457personalized cancer vaccine RO7198457, PCV RO7198457Immune response against tumor-associated antigens
NCT03213964IRecurrent advanced ovarian cancer only in abdomen/pelvisIntraperitoneal Delivery of Adaptive Natural Killer (NK) Cells (FATE-NK100) With Intraperitoneal Interleukin-2 in Women With Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal CancerView DrugsMinnesota
Drug(s) in Trial Other Drug Names Main Known Action
NK100NKG2C/CD57-expressing adaptive memory natural killer cells FATE-NK100Anti-tumor immune response
NCT03310541IAdvanced solid tumors with AKT1, AKT2, or AKT3 mutationsA Pilot Study of AZD5363 for Patients With Advanced Solid Tumors Harboring Mutations in AKT1, AKT2, or AKT3View DrugsNew Jersey, New York
Drug(s) in Trial Other Drug Names Main Known Action
CapivasertibAkt inhibitor AZD5363pan-AKT inhibitor
NCT02715284IAdvanced solid tumors (inc expansion)A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an Anti-PD-1 Monoclonal Antibody, in Patients With Advanced Solid TumorsView DrugsAlabama, Arizona, Arkansas, California, District of Columbia, Florida, Georgia, Illinois, Kansas, Maine, Massachusetts, Michigan, Minnesota, Missouri, New Mexico, New York, North Carolina, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, Tennessee, Texas, Utah, Virginia, Washington, West Virginia, Wisconsin
Drug(s) in Trial Other Drug Names Main Known Action
TSR-042anti-PD-1 monoclonal antibody TSR-042, ANB011, DostarlimabBlocks PD-L1/2 inhibition of T cells
NCT03313778IAdvanced solid tumors with high MSI or high TMB (in expansion)A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects With Resected Solid Tumors and in Combination With Pembrolizumab in Subjects With Unresectable Solid TumorsView DrugsFlorida, Massachusetts, New Jersey, New York, North Carolina, Tennessee
Drug(s) in Trial Other Drug Names Main Known Action
mRNA-4157mRNA-based personalized cancer vaccine mRNA-4157Anti-tumor immune response
PembrolizumabMK3475, SCH 900475, Lambrolizumab, KeytrudaBlocks PD-L1/2 inhibition of T cells
NCT01434316IAdvanced solid tumors including those with BRCA1/2 mutations (in expansion)Phase 1 Trial of ABT-888 and SCH727965 in Patients With Advanced Solid TumorsView DrugsMassachusetts
Drug(s) in Trial Other Drug Names Main Known Action
DinaciclibSCH 727965, CDK inhibitor SCH 727965CDK1, 2, 5, 9 inhibitor
VeliparibABT-888PARP inhibitor
NCT02433626IRecurrent ovarian cancerA Phase 1 Study of COTI-2 as Monotherapy or Combination Therapy for the Treatment of Advanced or Recurrent MalignanciesView DrugsTexas
Drug(s) in Trial Other Drug Names Main Known Action
CisplatinCACP, cis-DDP, cis-platinum, CDDP, Platinol, Abiplatin, Blastolem, Briplatin, Cisplatyl, Citoplatino, Citosin, Lederplatin, Metaplatin, Neoplatin, Placis, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platiran, Platistin, PlatosinDNA damaging agent
COTI-2mutant p53 activator COTI-2Mutant p53 activator
NCT02534922IRecurrent or persistent ovarian cancerPhase I Open-Label, Dose-Escalation and Pharmacokinetic Study of Subcutaneous Prolanta™ in Subjects With Recurrent or Persistent Epithelial Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube CancerView DrugsSouth Carolina
Drug(s) in Trial Other Drug Names Main Known Action
ProlantaProlactin receptor antagonist
NCT03017131IRecurrent or refractory ovarian cancerA Phase I Open Label Clinical Trial Evaluating the Safety and Efficacy of Adoptive Transfer of NY-ESO-1 TCR Engineered Autologous T Cells in Combination With Decitabine in Patients With Recurrent or Treatment Refractory Ovarian CancerView DrugsNew York
Drug(s) in Trial Other Drug Names Main Known Action
CyclophosphamideCiclofosfamida, Ciclofosfamide, Claphene, CP monohydrate, CPM, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphanum, Cytophosphane, Mitoxan, Syklofosfamid, Zytoxan, Clafen, Cytoxan, Neosar, Carloxan, Cicloxal, Cycloblastin, Cycloblastine, CYCLO-cell, Cyclostin, Cyclostine, Cytophosphan, Endoxan, Endoxana, Enduxan, Fosfaseron, Genoxal, Ledoxina, Procytox, SendoxanDNA damaging agent
Decitabine5-aza-dCyd, deoxyazacytidine, dezocitidine, DacogenDNA methylation inhibitor
Genetically Engineered NY-ESO-1-specific T LymphocytesImmune response against cancer expressing NY-ESO-1
NCT03030378IAdvanced solid tumorsA Phase 1 Study of MK-3475 (Pembrolizumab) in Combination With Recombinant Interleukin-12 in Patients With Solid TumorsView DrugsCalifornia, Colorado, Connecticut, Florida, Georgia, Iowa, Maryland, Massachusetts, Missouri, New Jersey, North Carolina, Ohio, Pennsylvania, Virginia
Drug(s) in Trial Other Drug Names Main Known Action
IL-12cytotoxic lymphocyte maturation factor interleukin-12, Ro 24-7472, recombinant interleukin-12, natural killer cell stimulatory factor NM-IL-12IL-12 receptor agonist
PembrolizumabMK3475, SCH 900475, Lambrolizumab, KeytrudaBlocks PD-L1/2 inhibition of T cells
NCT02498912IMUC16+ recurrent high grade serous ovarian cancer (> 2 prior therapies)A Phase I Clinical Trial of Cyclophosphamide Followed by Intravenous and Intraperitoneal Infusion of Autologous T Cells Genetically Engineered to Secrete IL-12 and to Target the MUC16ecto Antigen in Patients With Recurrent MUC16ecto+ Solid TumorsView DrugsNew York
Drug(s) in Trial Other Drug Names Main Known Action
4H11-28z/fIL-12/EFGRt-expressing autologous T lymphocytes4H11-28z/fIL-12/EFGRt+ genetically-modified T cells, autologous MUC16ecto-targeting EGFR-secreting T lymphocytesImmune response against cancer expressing CA125
CyclophosphamideCiclofosfamida, Ciclofosfamide, Claphene, CP monohydrate, CPM, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphanum, Cytophosphane, Mitoxan, Syklofosfamid, Zytoxan, Clafen, Cytoxan, Neosar, Carloxan, Cicloxal, Cycloblastin, Cycloblastine, CYCLO-cell, Cyclostin, Cyclostine, Cytophosphan, Endoxan, Endoxana, Enduxan, Fosfaseron, Genoxal, Ledoxina, Procytox, SendoxanDNA damaging agent
FludarabineFludara Oral, 2-F-ara-AMP, BeneflurDNA synthesis inhibitor
NCT03435250IAdvanced solid tumors with CDKN2A deletion (inc expansion)A Phase 1 Study of AG-270 in the Treatment of Subjects With Advanced Solid Tumors or Lymphoma With Homozygous Deletion of MTAPView DrugsConnecticut, Massachusetts, New York, Tennessee
Drug(s) in Trial Other Drug Names Main Known Action
AG-270methionine adenosyltransferase 2a (MAT2A) inhibitor
NCT03538028IAdvanced solid tumors (inc expansion)A Phase 1 Open-Label, Dose-Escalation, Safety and Tolerability Study of INCAGN02385 in Participants With Select Advanced MalignanciesView DrugsCalifornia, New Jersey, North Carolina, Tennessee
Drug(s) in Trial Other Drug Names Main Known Action
INCAGN02385Blocks LAG-3 inhibition of T cells
NCT03134638IAdvanced solid tumors (in ovarian expansion)A Phase 1 Study of SY-1365, a Selective CDK7 Inhibitor, in Adult Patients With Advanced Solid TumorsView DrugsAlabama, Arizona, California, Illinois, Massachusetts, New York, Oklahoma, Rhode Island, Tennessee, Texas
Drug(s) in Trial Other Drug Names Main Known Action
CarboplatinParaplatin, NovoplatinumDNA damaging agent
SY-1365SY 1365, CDK7 inhibitor SY-1365CDK7 inihibitor
NCT03517956IAdvanced solid tumors with FGFR over-expressionA Multicenter Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D) of the Combination of Rogaratinib and Copanlisib in Patients With FGFR-positive, Locally Advanced or Metastatic Solid TumorsView DrugsCalifornia, Illinois, Maryland, Massachusetts, Michigan, Nevada, New York, South Carolina, Texas
Drug(s) in Trial Other Drug Names Main Known Action
CopanlisibBAY 80-6946, MEK inhibitor BAY 80-6946, PI3K inhibitor BAY 80-6946pan-PI3K inhibitor
Rogaratinibpan-FGFR tyrosine kinase inhibitor BAY1163877, BAY1163877pan-FGFR kinase inhibitor
NCT03255070IAdvanced HER+ solid tumorsA Phase 1, Multicenter, Open-label, Multiple Dose-escalation Study of ARX788, Intravenously Administered as a Single Agent in Subjects With Advanced Cancers With HER2 ExpressionView DrugsMissouri
Drug(s) in Trial Other Drug Names Main Known Action
ARX788anti-HER2 antibody-drug conjugate ARX788, ADC ARX788ADC: anti-HER2 + microtubule destabilizer (MMAF)
NCT03330561IAdvanced HER2+ solid tumors (inc expansion)A Phase 1, Open-Label, Dose Escalation Study of PRS-343 in Patients With HER2-Positive Advanced or Metastatic Solid TumorsView DrugsArizona, California, District of Columbia, Maryland, New York, Pennsylvania, Tennessee, Texas
Drug(s) in Trial Other Drug Names Main Known Action
PRS-343anti-HER2 monoclonal antibody/anti-CD137 anticalin bispecific fusion protein PRS-343Immune response against cancer expressing HER2
NCT03585764IRecurrent or persistent FRalpha+ high grade serous ovarian cancerPhase I Clinical Trial of Adoptive Transfer of Autologous Folate Receptor - Alpha Redirected T Cells for Recurrent High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal CancerView DrugsPennsylvania
Drug(s) in Trial Other Drug Names Main Known Action
CyclophosphamideCiclofosfamida, Ciclofosfamide, Claphene, CP monohydrate, CPM, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphanum, Cytophosphane, Mitoxan, Syklofosfamid, Zytoxan, Clafen, Cytoxan, Neosar, Carloxan, Cicloxal, Cycloblastin, Cycloblastine, CYCLO-cell, Cyclostin, Cyclostine, Cytophosphan, Endoxan, Endoxana, Enduxan, Fosfaseron, Genoxal, Ledoxina, Procytox, SendoxanDNA damaging agent
FludarabineFludara Oral, 2-F-ara-AMP, BeneflurDNA synthesis inhibitor
MOv19-BBz CAR TImmune response against cancer expressing folate receptor
NCT03486301IAdvanced solid tumors (inc expansion)Phase 1 Open-Label Dose Escalation Study of BDB001 as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid TumorsView DrugsFlorida, Tennessee, Texas
Drug(s) in Trial Other Drug Names Main Known Action
BDB001TLR agonist and immune cell stimulator
PembrolizumabMK3475, SCH 900475, Lambrolizumab, KeytrudaBlocks PD-L1/2 inhibition of T cells
NCT03144661IRecurrent advanced serous ovarian cancerA Phase 1, Open-Label, Dose-Escalation and Expansion, Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other MalignanciesView DrugsAlabama, New York
Drug(s) in Trial Other Drug Names Main Known Action
INCB062079FGFR4 inhibitor
NCT03059823IAdvanced solid tumors (inc expansion)A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of INCMGA00012 in Patients With Advanced Solid TumorsView DrugsArizona, Michigan, New Jersey, North Carolina, Texas, Virginia
Drug(s) in Trial Other Drug Names Main Known Action
MGA012anti-PD-1 monoclonal antibody MGA012, INCMGA00012Blocks PD-L1 inhibition of T cells
NCT03431948IAdvanced solid tumors (amenable to radiation treatment)Platform Phase 1 Study Investigating the Safety of Stereotactic Body Radiotherapy (SBRT) With Immuno-oncology Agents for the Treatment of Multiple Metastases in Advanced Solid TumorsView DrugsIllinois
Drug(s) in Trial Other Drug Names Main Known Action
Cabiralizumabanti-CSF1R monoclonal antibody FPA008, FPA008CSF1R antagonist and tumor-associated macrophage inhibitor
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cells
Radiation TherapyRadiotherapy, Irradiation
UrelumabBMS-663513, anti-CD137 monoclonal antibody, anti-4-1BB monoclonal antibodyStimulates 4-1BB (CD137) to increase T cells and immune response
NCT03691376IRecurrent or refractory NY-ESO-1+ ovarian cancerA Phase I, Open Label Study Evaluating the Safety and Efficacy of Adoptive Transfer of Autologous NY-ESO-1 CD8-TCR Engineered T Cells and NY-ESO-1 CD4-TCR Engineered Hematopoietic Stem Cells (HSC) After a Myeloablative Conditioning Regimen, With Administration of IL-2 in Patients With Recurrent or Treatment Refractory Ovarian, Fallopian Tube or Primary Peritoneal CancerView DrugsNew York
Drug(s) in Trial Other Drug Names Main Known Action
AldesleukinIL-2 receptor agonist
MelphalanSarcolysin, Alkeran, Alkerana, Melfalan, Phenylalanine mustardDNA damaging agent
NY-ESO-1 CD4-TCR Engineered Hematopoietic Stem Cells (HSC)Immune response against cancer expressing NY-ESO-1
NY-ESO-1 CD8-TCR Engineered T CellsImmune response against cancer expressing NY-ESO-1
NCT03502733IAdvanced solid tumorsPhase Ib Combination Study of Copanlisib and Nivolumab in Advanced Solid Tumors and LymphomasView DrugsMaryland, Texas
Drug(s) in Trial Other Drug Names Main Known Action
CopanlisibBAY 80-6946, MEK inhibitor BAY 80-6946, PI3K inhibitor BAY 80-6946pan-PI3K inhibitor
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cells
NCT03318900IRecurrent high grade ovarian cancerPhase I/Ib Study of Adoptive Cellular Therapy Using Autologous IL-21-Primed CD8+ Tumor Antigen-Specific T Cells in Combination With Utomilumab (PF-05082566) in Patients With Platinum Resistant Ovarian CancerView DrugsTexas
Drug(s) in Trial Other Drug Names Main Known Action
CyclophosphamideCiclofosfamida, Ciclofosfamide, Claphene, CP monohydrate, CPM, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphanum, Cytophosphane, Mitoxan, Syklofosfamid, Zytoxan, Clafen, Cytoxan, Neosar, Carloxan, Cicloxal, Cycloblastin, Cycloblastine, CYCLO-cell, Cyclostin, Cyclostine, Cytophosphan, Endoxan, Endoxana, Enduxan, Fosfaseron, Genoxal, Ledoxina, Procytox, SendoxanDNA damaging agent
IL-21-Primed CD8+ Tumor Antigen-Specific T Cellsadoptively transferred central memory-type CTL targeting ovarian cancer antigensImmune response against cancer expressing PRAME and/or COL6A3
UtomilumabPF-05082566Stimulates 4-1BB (CD137) to increase T cells and immune response
NCT03724890IAdvanced solid tumorsA Multicenter, Open-Label, Dose Escalation Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of the DNA-PK Inhibitor M3814 in Combination With Avelumab With and Without Palliative Radiotherapy in Participants With Selected Advanced Solid TumorsView DrugsCalifornia, Florida, Illinois, New York, Ohio, Oklahoma, Tennessee
Drug(s) in Trial Other Drug Names Main Known Action
AvelumabAnti programmed death ligand 1 monoclonal antibody, Anti-PD-L1, MSB0010718C, BavencioBlocks PD-L1 inhibition of T cells
M3814DNA-PK inhibitor MSC2490484ADNA-PK inhibitor
Radiation TherapyRadiotherapy, Irradiation
NCT03725436IAdvanced solid tumors that are TP53 WTA Phase 1b Study of ALRN-6924 in Combination With Paclitaxel in Wild-Type TP53 Advanced or Metastatic Solid Tumors Including Estrogen-Receptor Positive Breast CancerView DrugsTexas
Drug(s) in Trial Other Drug Names Main Known Action
ALRN-6924MDM2/MDMX inhibitor ALRN-6924MDM2 and MDMX inhibitor
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXLMicrotubule stabilizer/mitotic inhibitor
NCT03719326IAdvanced ovarian cancer (inc expansion)A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Breast and Gynecologic MalignanciesView DrugsArizona, Colorado, Florida, Maryland, Nevada, North Carolina, Oregon, Texas, Virginia, Washington
Drug(s) in Trial Other Drug Names Main Known Action
AB928AB928, a dual antagonist of the A2aR and A2bR adenosine receptorsBlocks adenosine A2A/B receptors inhibition of T cells
IPI-549PI3K-gamma inhibitor IPI-549PI3K gamma inhibitor
Liposomal doxorubicinDoxil, Dox-SL, Evacet, LipoDox, liposomal doxorubicin, Pegylated Liposomal Doxorubicin HydrochlorideTopoisomerase II inhibitor
NCT03139370IAdvanced MAGE-A3/A6+, HLA-DPB1*04:01+ (inc expansion)A Phase 1 Study Evaluating the Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Subjects With Advanced CancersView DrugsCalifornia, Florida, Massachusetts, New York, Texas
Drug(s) in Trial Other Drug Names Main Known Action
CyclophosphamideCiclofosfamida, Ciclofosfamide, Claphene, CP monohydrate, CPM, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphanum, Cytophosphane, Mitoxan, Syklofosfamid, Zytoxan, Clafen, Cytoxan, Neosar, Carloxan, Cicloxal, Cycloblastin, Cycloblastine, CYCLO-cell, Cyclostin, Cyclostine, Cytophosphan, Endoxan, Endoxana, Enduxan, Fosfaseron, Genoxal, Ledoxina, Procytox, SendoxanDNA damaging agent
FludarabineFludara Oral, 2-F-ara-AMP, BeneflurDNA synthesis inhibitor
KITE-718MAGEA3/A6-targeted TCR-transduced T cells KITE-718, autologous MAGE-A3/A6-specific TCR gene-engineered lymphocytes KITE-718immune response against cancer expressing MAGE-A3/A6
NCT03739931IAdvanced solid tumors (inc expansion) - intratumoral injectionA Phase 1, Open-Label, Multicenter, Dose Escalation Study of mRNA-2752, a Lipid Nanoparticle Encapsulating mRNAs Encoding Human OX40L, IL-23, and IL-36γ, for Intratumoral Injection Alone and in Combination With Immune Checkpoint BlockadeView DrugsColorado, Connecticut, Florida, Michigan, Tennessee
Drug(s) in Trial Other Drug Names Main Known Action
DurvalumabAnti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, ImfinziBlocks PD-L1 inhibition of T cells
mRNA-2752lipid nanoparticle-encapsulated OX40L, IL23, IL36gamma mRNA-2752
Tremelimumabanti-CTLA4 human monoclonal antibody CP-675,206, CP-675, CP-675,206, CP-675206, TicilimumabBlocks CTLA-4 inhibition of T cells
NCT03875287IAdvanced solid tumorsA Phase I Dose-Escalation Study of E7727, an Oral Cytidine Deaminase Inhibitor (CDAi) With Oral Decitabine in Subjects With Solid TumorsView DrugsMaryland
Drug(s) in Trial Other Drug Names Main Known Action
ASTX727CDA inhibitor E7727/decitabine combination agent ASTX727DNA methylation inhibitor
NCT03821935IAdvanced solid tumorsA Phase 1 First-in Human, Multi-Center, Open Label Dose-Escalation Study to Determine the Safety, Tolerability, Pharmacokinetics and RP2D of ABBV-151 as a Single Agent and in Combination With ABBV-181 in Subjects With Locally Advanced or Metastatic Solid TumorsView DrugsConnecticut, North Carolina, Texas
Drug(s) in Trial Other Drug Names Main Known Action
ABBV-151ARGX-115binds GARP in complex with inactive TGF-beta preventing release of active TGF-beta
ABBV-181anti-PD1 monoclonal antibody ABBV-181Blocks PD-L1 inhibition of T cells
NCT03831295IAdvanced solid tumorsIntratumoral Injection of SD-101, an Immunostimulatory CpG Oligonucleotide, in Combination With BMS- 986178, an OX40 Agonist Antibody, in Advanced Solid Malignancies [CA012-014]View DrugsCalifornia
Drug(s) in Trial Other Drug Names Main Known Action
BMS-986178anti-OX40 antibody BMS 986178Stimulates OX40 to increase T cell activation and immune response
SD-101TLR9 agonist SD-101, ISS-ODN SD-101TLR9 agonist and immune cell activator
NCT03840200IRecurrent ovarian cancerA Phase Ib, Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Ipatasertib in Combination With Rucaparib in Patients With Advanced Breast, Ovarian, or Prostate CancerView DrugsPennsylvania
Drug(s) in Trial Other Drug Names Main Known Action
IpatasertibGDC-0068, Akt Inhibitor GDC-0068, RG7440pan-AKT inhibitor
RucaparibAG-014699, PF 01367338, CO-338, RubracaPARP inhibitor
NCT03841110IAdvanced solid tumors (inc expansion)FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors (Phase 1)View DrugsCalifornia, Minnesota, Texas
Drug(s) in Trial Other Drug Names Main Known Action
AtezolizumabTecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446Blocks PD-L1 inhibition of T cells
CyclophosphamideCiclofosfamida, Ciclofosfamide, Claphene, CP monohydrate, CPM, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphanum, Cytophosphane, Mitoxan, Syklofosfamid, Zytoxan, Clafen, Cytoxan, Neosar, Carloxan, Cicloxal, Cycloblastin, Cycloblastine, CYCLO-cell, Cyclostin, Cyclostine, Cytophosphan, Endoxan, Endoxana, Enduxan, Fosfaseron, Genoxal, Ledoxina, Procytox, SendoxanDNA damaging agent
FludarabineFludara Oral, 2-F-ara-AMP, BeneflurDNA synthesis inhibitor
FT500Anti-tumor immune response
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cells
PembrolizumabMK3475, SCH 900475, Lambrolizumab, KeytrudaBlocks PD-L1/2 inhibition of T cells
NCT03556228IAdvanced solid tumors (inc expansion)An Open-Label, Multiple-Dose, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of VMD-928 in Subjects With Solid Tumors or LymphomaView DrugsCalifornia
Drug(s) in Trial Other Drug Names Main Known Action
VMD-928TrkA inhibitor VMD-928TRK kinase inhibitor
NCT03968406IRecurrent ovarian cancer - without ascitesPhase I Study of Talazoparib in Combination With Radiation Therapy for Locally Recurrent Gynecologic CancersView DrugsTexas
Drug(s) in Trial Other Drug Names Main Known Action
Radiation TherapyRadiotherapy, Irradiation
TalazoparibTalazoparib Tosylate, BMN-673, MDV3800PARP inhibitor
NCT03219268IAdvanced solid tumors (inc expansion)A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of MGD013, A Bispecific DART® Protein Binding PD-1 and LAG-3 in Patients With Unresectable or Metastatic NeoplasmsView DrugsArizona, California, Florida, Illinois, Maryland, Massachusetts, North Carolina, Ohio, Oklahoma, Pennsylvania, Tennessee, Texas
Drug(s) in Trial Other Drug Names Main Known Action
Margetuximabanti-HER2/c-erbB2 monoclonal antibody, anti-HER2 mAb MGAH22HER2 antagonist
MGD013anti-PD-1/anti-LAG-3 DART protein MGD013, dual-affinity retargeting protein MGD013Blocks LAG-3 and PD-1 inhibition of T cells
NCT03416335IAdvanced solid tumors (inc expansion)A First-in-Human Phase I Trial to Determine the Safety and the Pharmacokinetic Profile of DSP-0509, a Synthetic Toll-Like Receptor 7 (TLR-7) Agonist, in Adult Patients With Advanced Solid TumorsView DrugsIndiana, Texas
Drug(s) in Trial Other Drug Names Main Known Action
DSP-0509toll-like receptor 7 agonist DSP-0509TLR7 agonist and immune cell activator
NCT03628677IAdvanced solid tumors (inc expansion)A Phase 1 Study to Evaluate the Safety and Tolerability of AB154 Monotherapy and Combination Therapy in Participants With Advanced MalignanciesView DrugsNorth Carolina, Texas, Washington
Drug(s) in Trial Other Drug Names Main Known Action
AB122Blocks PD-L1 inhibition of T cells
AB154Blocks T cell binding to CD112 and CD155 to enable activation of CD226 signaling in NK and CD8 T cells
NCT03920839IAdvanced solid tumors at first recurrenceA Phase 1b Combination Study of INCMGA00012 Plus Chemotherapy in Participants With Advanced Solid Tumors (POD1UM-105)View DrugsCalifornia
Drug(s) in Trial Other Drug Names Main Known Action
CarboplatinParaplatin, NovoplatinumDNA damaging agent
CisplatinCACP, cis-DDP, cis-platinum, CDDP, Platinol, Abiplatin, Blastolem, Briplatin, Cisplatyl, Citoplatino, Citosin, Lederplatin, Metaplatin, Neoplatin, Placis, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platiran, Platistin, PlatosinDNA damaging agent
GemcitabineGemzarRibonucleotide reductase and DNA synthesis inhibitor
MGA012anti-PD-1 monoclonal antibody MGA012, INCMGA00012Blocks PD-L1 inhibition of T cells
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXLMicrotubule stabilizer/mitotic inhibitor
PemetrexedPemetrexed disodium, AlimtaDHFR and Thymidylate synthase inhibitor
NCT03240861IAdvanced NY-ESO-1+ solid tumorsAdoptive Transfer of NY-ESO-1 TCR Engineered Peripheral Blood Mononuclear Cells (PBMC) and Peripheral Blood Stem Cells (PBSC) After a Myeloablative Conditioning Regimen, With Administration of Interleukin-2, in Patients With Advanced MalignanciesView DrugsCalifornia
Drug(s) in Trial Other Drug Names Main Known Action
AldesleukinIL-2 receptor agonist
BusulfanBusulfex, busulphan, CB-2041, Glyzophrol, GT-41, joacamine, leucosulfan, mielucin, misulban, misulfan, mitosan, myeleukon, myeloleukon, myelosan, mylecytan, myleran, sulfabutin, WR-19508DNA damaging agent
FludarabineFludara Oral, 2-F-ara-AMP, BeneflurDNA synthesis inhibitor
NY-ESO-1 TCR transgenic T cells and NY-ESO-1 TCR/sr39TK transgenic stem cellsImmune response against cancer expressing NY-ESO-1
NCT03444714IAdvanced solid tumors with lesion amenable to palliative radiotherapy - intratumoral injectionPhase I Dose-Escalating Study of RiMO-301 With Radiation in Advanced TumorsView DrugsIllinois
Drug(s) in Trial Other Drug Names Main Known Action
Radiation TherapyRadiotherapy, Irradiation
RiMO-301metal-organic framework (MOF) compound RiMO-301, MOF compound RiMO-301following intratumoral injection and radiation induces ROS-mediated DNA damage
NCT03156114IAdvanced solid tumors with high MSI or high TMB and prior checkpoint inhibitor treatment (in expansion)An Open Label, Phase I Dose-finding Study of BI 754111 in Combination With BI 754091 in Patients With Advanced Solid Cancers Followed by Expansion Cohorts at the Selected Dose of the Combination in Patients With Non-small Cell Lung Cancer and Other Solid TumorsView DrugsFlorida, Oklahoma, Tennessee, Wisconsin
Drug(s) in Trial Other Drug Names Main Known Action
BI 754091anti-PD-1 monoclonal antibody BI 754091Blocks PD-L1/2 inhibition of T cells
BI 754111Blocks LAG-3 inhibition of T cells
NCT02990481IAdvanced solid tumors (in expansion)A Phase 1, Multicenter, Open-label, Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of TRK-950 Given Intravenously in Patients With Advanced Solid TumorsView DrugsArizona
Drug(s) in Trial Other Drug Names Main Known Action
TRK-950monoclonal antibody TRK-950Undisclosed mechanism
NCT03894540IAdvanced solid tumors (inc expansion)A Phase I, Open Label, Dose Escalation and Dose Expansion Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumour Activity of IPN60090 as Single Agent and in Combination in Patients With Advanced Solid TumoursView DrugsTexas
Drug(s) in Trial Other Drug Names Main Known Action
IPN60090Undisclosed mechanism
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXLMicrotubule stabilizer/mitotic inhibitor
PembrolizumabMK3475, SCH 900475, Lambrolizumab, KeytrudaBlocks PD-L1/2 inhibition of T cells
NCT03893955IAdvanced solid tumorsA Phase 1, Multicenter, Open-Label Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 and ABBV-368 With and Without ABBV-181 in Subjects With Locally Advanced or Metastatic Solid TumorsView DrugsAlabama, California, Connecticut, North Carolina, Texas, Virginia
Drug(s) in Trial Other Drug Names Main Known Action
ABBV-368Stimulates OX40 to increase T cell activation and immune response
ABBV-927anti-CD40 agonist monoclonal antibody ABBV-927Stimulates CD40 to increase/activate antigen-presenting cells and enhance immune response

If you have any questions or would like help with your search, please call us at: 858-264-5124 or email us at patientsupport@clearityfoundation.org.